
    
      This is a Phase 1, single-center, prospective, randomized, double-blind study of ascending
      single doses of CD101 Injection administered IV to healthy adult subjects. In this study,
      subjects in 4 cohorts of 8 subjects, each will be randomized to receive single IV doses of
      CD101 Injection or placebo. Dose levels of CD101 to be assessed will follow an ascending
      single-dose regimen.
    
  